AbbVie Inc.·4

Mar 3, 6:14 PM ET

Thakkar Roopal 4

Research Summary

AI-generated summary

Updated

AbbVie EVP Roopal Thakkar Pays Tax Withholding via Disposal of 8,037 Shares

What Happened
Roopal Thakkar, Executive Vice President, R&D and Chief Scientific Officer of AbbVie (ABBV), disposed of 8,037 shares on February 27, 2026 at $232.08 per share to satisfy a tax or exercise-related liability. The disposition equals $1,865,227. The transaction is reported under code F (payment of exercise price or tax liability), indicating these shares were used to cover tax/option-related obligations rather than a voluntary open-market sale.

Key Details

  • Transaction date: 2026-02-27; Form 4 filed: 2026-03-03 (filed within the standard two-business-day window).
  • Price and amount: 8,037 shares at $232.08 per share; total value $1,865,227.
  • Transaction code: F — payment of exercise price or tax liability (share withholding).
  • Shares owned after transaction: not specified in the provided filing.
  • Footnote: F1 notes a balance in the AbbVie Savings program as of Feb 20, 2026 (including dividend reinvestment); this balance was inadvertently omitted from a Form 3 filed Dec 22, 2023.

Context
Code F disposals typically reflect share withholding to cover taxes or option exercise costs (a routine administrative action), not an open-market sale intended to realize gains. Such withholdings are common following option exercises or vesting events and do not necessarily indicate the insider’s view on the company’s prospects.